JP2018515101A5 - - Google Patents

Info

Publication number

JP2018515101A5

JP2018515101A5 JP2017559314A JP2017559314A JP2018515101A5 JP 2018515101 A5 JP2018515101 A5 JP 2018515101A5 JP 2017559314 A JP2017559314 A JP 2017559314A JP 2017559314 A JP2017559314 A JP 2017559314A JP 2018515101 A5 JP2018515101 A5 JP 2018515101A5

Authority

JP

Japan

Prior art keywords

uricase

peg

pharmaceutical composition

monomer

seq

Prior art date

2016-05-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108010092464 Urate Oxidase Proteins 0.000 claims description 45
• 239000000178 monomer Substances 0.000 claims description 16
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 10
• 201000005569 Gout Diseases 0.000 claims description 9
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 8
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 8
• 229940116269 uric acid Drugs 0.000 claims description 8
• 239000002773 nucleotide Substances 0.000 claims description 6
• 125000003729 nucleotide group Chemical group 0.000 claims description 6
• 235000018417 cysteine Nutrition 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 3
• 239000013078 crystal Substances 0.000 claims description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
• 230000000174 oncolytic effect Effects 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 201000001431 Hyperuricemia Diseases 0.000 claims description 2
• 239000002202 Polyethylene glycol Substances 0.000 claims 13
• 229920001223 polyethylene glycol Polymers 0.000 claims 13
• 239000008194 pharmaceutical composition Substances 0.000 claims 11
• 125000003275 alpha amino acid group Chemical group 0.000 claims 4
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 3
• DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims 3
• 210000004899 c-terminal region Anatomy 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 230000037430 deletion Effects 0.000 claims 2
• 238000012217 deletion Methods 0.000 claims 2
• 108090000790 Enzymes Proteins 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
• 238000000034 method Methods 0.000 description 9
• 150000001413 amino acids Chemical group 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1